SEC Form 4 · accession 0001193125-26-368244
Rapport Therapeutics, Inc. · RAPP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Krishnaswamy Yeleswaram
Officer — Chief Development Officer
Period of report
Aug 24, 2026
Accepted (ET)
Aug 26, 2026 · 4:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0002012593
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 24, 2026 | S | 13,160 | $49.9983 | D | 232,862 | D | |
| Common StockF3 | Aug 25, 2026 | S | 20,799 | $50.3111 | D | 212,063 | D | |
| Common StockF4 | Aug 25, 2026 | S | 16,201 | $51.0576 | D | 195,862 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.91 to $51.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.